The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.
The UK NIPT firm said that is creating a provision of £500,000 to cover expected expenses related to litigation involving Illumina.
The partners will leverage IME's rare cell isolation technology, a microchip containing a microfabricated filter membrane to isolate and enrich fetal cells from maternal blood.
Patent law experts said the ruling provides further clarity over what is and is not patentable within the broader molecular diagnostics field.
The results were presented at the ESHG meeting in Scotland this weekend and could potentially influence how NIPT is offered in those countries.
With evidence of significant variation among consent procedures in the NIPT space, and the potential for a lack of awareness about incidental findings, Bianchi recommends the field come together to standardize procedures and education.
In addition to offering NIPTs, Natera is eyeing the cancer diagnostics space.
The UK firm is using MALDI-TOF mass spec technology to develop the test as a screening tool for the disorder as early as eight weeks into a pregnancy.
The company said that the financing will go toward sales and marketing, as well as R&D on its Panorama NIPT, diagnostic tests for cancer, and clinical trials.
Three new studies, published online in the New England Journal of Medicine, shed light on how NIPT may be best integrated into clinical care for all pregnant women.
NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.
Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.
In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.